Cancer biologists have identified important drivers that enable tumors to change their behavior and evade anticancer therapies.
By studying tumors in cell lines, mice and human samples, the team documented genetic signals that promote the conversion of cancer cells from one stage to another. The journal Nature Cell Biology published the research.
“Although we focused on breast cancer in this study, we believe the identified mechanism can apply to all treatment-resistant cancers,” said study senior author.
The ability of cancer cells to take different shapes, to grow faster or slower, and to vary in size is called “phenotypic plasticity.” Cancers that acquire plasticity often are more dangerous, becoming metastatic and resistant to many targeted therapies, the senior author said.
The authors show that endocrine resistance is associated with enhanced phenotypic plasticity, indicated by a general downregulation of luminal/epithelial differentiation markers and upregulation of basal/mesenchymal invasive markers.
Consistently, similar gene expression changes are found in clinical breast tumours and patient-derived xenograft samples that are resistant to endocrine therapies.
Mechanistically, the differential interactions between oestrogen receptor α and other oncogenic transcription factors, exemplified by GATA3 and AP1, drive global enhancer gain/loss reprogramming, profoundly altering breast cancer transcriptional programs. The functional studies in multiple culture and xenograft models reveal a coordinated role of GATA3 and AP1 in re-organizing enhancer landscapes and regulating cancer phenotypes.
The team’s next step is to screen new drugs, in the form of small molecules, that disrupt the genetic signals underlying tumor plasticity. Such a drug could be administered along with current targeted therapies to eliminate the problem of resistance to those treatments, the senior author said.
“If we target the drivers of phenotypic plasticity, we may increase the effectiveness of many therapies and cure more cancers,” the author said.
https://news.uthscsa.edu/23378-2/
https://www.nature.com/articles/s41556-020-0514-z
Cancer resistance driven by transcription factor assembly at the enhancers
- 1,449 views
- Added
Edited
Latest News
New origin of deep brain waves
By newseditor
Posted 17 Apr
Starving cells hijack prote…
By newseditor
Posted 17 Apr
Miniature battery-free epid…
By newseditor
Posted 17 Apr
Molecular causes of differe…
By newseditor
Posted 16 Apr
Cell's 'garbage disposal' h…
By newseditor
Posted 16 Apr
Other Top Stories
Mapping ketamine's effects on brain
Read more
Cell-type-specific genetic risk contributes to distinct stages of A…
Read more
Hot hatha yoga potent antidepressant in a clinical trial
Read more
How bone marrow peripheral nerves promote hematopoietic and vascula…
Read more
Finding biomarker for inflammatory bowel disease using reverse meta…
Read more
Protocols
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Modular dual-color BiAD sen…
By newseditor
Posted 31 Mar
Publications
The immunobiology of herpes…
By newseditor
Posted 17 Apr
Circulating microbiome DNA…
By newseditor
Posted 17 Apr
Spindle oscillations in com…
By newseditor
Posted 17 Apr
Oligodendroglial macroautop…
By newseditor
Posted 17 Apr
COPII with ALG2 and ESCRTs…
By newseditor
Posted 17 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar